The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Esophagitis


Psychiatry related information on Esophagitis


High impact information on Esophagitis


Chemical compound and disease context of Esophagitis


Biological context of Esophagitis

  • The animals were killed 16 weeks after operation or injection, the entire esophageal mucosa was harvested, and mutation frequency was determined through standard Big Blue Mutagenesis Assay. RESULTS: Gross esophagitis was evident in all operated animals [16].
  • Their average number per high-power field was low in benign squamous epithelium away from tumors (average 0.8/high-power field) but much higher in biopsies with the other categories of histology, especially those with active esophagitis and infection (6.3/high-power field) [17].
  • Similarly, EFS-induced but not ACh-induced muscle contraction decreased in esophagitis and after incubation in PGE2 and PAF C-16 [18].
  • Compared with controls, repeated acid perfusion induced erosive esophagitis and significant esophageal shortening, associated with enhanced LM responses to carbachol, a significantly depolarized resting membrane potential, and abnormal spike patterns [19].
  • As previously shown, refluxers with esophagitis also had more frequent acid gastroesophageal reflux and prolonged gastric emptying [20].

Anatomical context of Esophagitis

  • The patients with erosive esophagitis also had significantly diminished lower esophageal sphincter pressures and increased frequency and duration of gastroesophageal reflux episodes [21].
  • A 71-year-old woman experienced severe, acute esophagitis and severe stricture of the esophagus due to oral alendronate therapy [22].
  • Also alendronate is far more damaging at acidic than at neutral pH, suggesting its association with esophagitis requires gastric acid for expression [23].
  • Our objectives were to determine whether esophageal IELs express the recently described cytotoxic T-cell (CTLs) markers, TIA-1 and granzyme-B, and whether the number of CTLs correlates with well-defined endoscopic, clinical, and histological features of esophagitis [24].
  • Routinely processed hematoxylin and eosin (H&E)-stained slides of esophageal mucosal biopsies from 14 patients with both active esophagitis and multinucleated epithelial giant cells were evaluated for a variety of inflammatory and epithelial features [25].

Gene context of Esophagitis

  • There was also no significant increase in COX-2 expression in patients with esophagitis or in those who used nonsteroidal anti-inflammatory drugs [26].
  • It is noteworthy, however, that the CDX2 mRNA expression was initiated at the stage of esophagitis, when neither CDX1 nor intestine-specific genes had emerged yet [27].
  • All operated mice (6 ApcMin/+, 12 WT, and 4 Trp53-/-) had esophagitis, with squamous hyperplasia and early focal ulceration [28].
  • Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism [29].
  • We investigated the roles of prostaglandin (PG) E2 and cyclooxygenase (COX) isoenzymes in the mucosal defense of the esophagus, using subtype-selective EP agonists and antagonists as well as various COX inhibitors, in an acute rat esophagitis model [30].

Analytical, diagnostic and therapeutic context of Esophagitis


  1. Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. Lundell, L., Miettinen, P., Myrvold, H.E., Pedersen, S.A., Thor, K., Andersson, A., Hattlebakk, J., Havu, N., Janatuinen, E., Levander, K., Liedman, B., Nyström, P. Gastroenterology (1999) [Pubmed]
  2. Barrett's esophagus in children: a consequence of chronic gastroesophageal reflux. Dahms, B.B., Rothstein, F.C. Gastroenterology (1984) [Pubmed]
  3. Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Marks, R.D., Richter, J.E., Rizzo, J., Koehler, R.E., Spenney, J.G., Mills, T.P., Champion, G. Gastroenterology (1994) [Pubmed]
  4. Comorbid occurrence of laryngeal or pulmonary disease with esophagitis in United States military veterans. el-Serag, H.B., Sonnenberg, A. Gastroenterology (1997) [Pubmed]
  5. High incidence of esophageal motor disorders in consecutive patients with globus sensation. Moser, G., Vacariu-Granser, G.V., Schneider, C., Abatzi, T.A., Pokieser, P., Stacher-Janotta, G., Gaupmann, G., Weber, U., Wenzel, T., Roden, M. Gastroenterology (1991) [Pubmed]
  6. Ranitidine therapy for esophagitis in children with developmental disabilities. Kaufman, S.S., Loseke, C.A., Young, R.J., Perry, D.A. Clinical pediatrics. (1996) [Pubmed]
  7. Esophagitis associated with the use of alendronate. de Groen, P.C., Lubbe, D.F., Hirsch, L.J., Daifotis, A., Stephenson, W., Freedholm, D., Pryor-Tillotson, S., Seleznick, M.J., Pinkas, H., Wang, K.K. N. Engl. J. Med. (1996) [Pubmed]
  8. A comparison of five maintenance therapies for reflux esophagitis. Vigneri, S., Termini, R., Leandro, G., Badalamenti, S., Pantalena, M., Savarino, V., Di Mario, F., Battaglia, G., Mela, G.S., Pilotto, A. N. Engl. J. Med. (1995) [Pubmed]
  9. Doxycycline-induced esophagitis. Amendola, M.A., Spera, T.D. JAMA (1985) [Pubmed]
  10. Esophagitis related to cromolyn. Israel, R.H., Wood, J. JAMA (1979) [Pubmed]
  11. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. Blanchard, C., Wang, N., Stringer, K.F., Mishra, A., Fulkerson, P.C., Abonia, J.P., Jameson, S.C., Kirby, C., Konikoff, M.R., Collins, M.H., Cohen, M.B., Akers, R., Hogan, S.P., Assa'ad, A.H., Putnam, P.E., Aronow, B.J., Rothenberg, M.E. J. Clin. Invest. (2006) [Pubmed]
  12. An etiological role for aeroallergens and eosinophils in experimental esophagitis. Mishra, A., Hogan, S.P., Brandt, E.B., Rothenberg, M.E. J. Clin. Invest. (2001) [Pubmed]
  13. Esophagitis healing with ranitidine. Bianchi Porro, G., Pace, F., Lazzaroni, M. Gastroenterology (1987) [Pubmed]
  14. Sucralfate prevents experimental peptic esophagitis in rabbits. Schweitzer, E.J., Bass, B.L., Johnson, L.F., Harmon, J.W. Gastroenterology (1985) [Pubmed]
  15. Fluconazole versus itraconazole for candida esophagitis in acquired immunodeficiency syndrome. Candida Esophagitis. Barbaro, G., Barbarini, G., Calderon, W., Grisorio, B., Alcini, P., Di Lorenzo, G. Gastroenterology (1996) [Pubmed]
  16. The mutagenic potential of duodenoesophageal reflux. Theisen, J., Peters, J.H., Fein, M., Hughes, M., Hagen, J.A., Demeester, S.R., Demeester, T.R., Laird, P.W. Ann. Surg. (2005) [Pubmed]
  17. Nature and significance of cells with irregular nuclear contours in esophageal mucosal biopsies. Mangano, M.M., Antonioli, D.A., Schnitt, S.J., Wang, H.H. Mod. Pathol. (1992) [Pubmed]
  18. Platelet-activating factor and prostaglandin E2 impair esophageal ACh release in experimental esophagitis. Cheng, L., Cao, W., Fiocchi, C., Behar, J., Biancani, P., Harnett, K.M. Am. J. Physiol. Gastrointest. Liver Physiol. (2005) [Pubmed]
  19. Esophagitis-related esophageal shortening in opossum is associated with longitudinal muscle hyperresponsiveness. White, R.J., Zhang, Y., Morris, G.P., Paterson, W.G. Am. J. Physiol. Gastrointest. Liver Physiol. (2001) [Pubmed]
  20. Duodenogastric reflux and reflux esophagitis. Little, A.G., Martinez, E.I., DeMeester, T.R., Blough, R.M., Skinner, D.B. Surgery (1984) [Pubmed]
  21. Esophagitis in scleroderma. Prevalence and risk factors. Zamost, B.J., Hirschberg, J., Ippoliti, A.F., Furst, D.E., Clements, P.J., Weinstein, W.M. Gastroenterology (1987) [Pubmed]
  22. Alendronate-induced esophagitis: case report of a recently recognized form of severe esophagitis with esophageal stricture--radiographic features. Ryan, J.M., Kelsey, P., Ryan, B.M., Mueller, P.R. Radiology. (1998) [Pubmed]
  23. Physiological and morphological effects of alendronate on rabbit esophageal epithelium. Dobrucali, A., Tobey, N.A., Awayda, M.S., Argote, C., Abdulnour-Nakhoul, S., Shao, W., Orlando, R.C. Am. J. Physiol. Gastrointest. Liver Physiol. (2002) [Pubmed]
  24. Assessment and diagnostic utility of the cytotoxic T-lymphocyte phenotype using the specific markers granzyme-B and TIA-1 in esophageal mucosal biopsies. Resnick, M.B., Finkelstein, Y., Weissler, A., Levy, J., Yakirevich, E. Hum. Pathol. (1999) [Pubmed]
  25. Multinucleated epithelial giant cell changes in esophagitis: a clinicopathologic study of 14 cases. Singh, S.P., Odze, R.D. Am. J. Surg. Pathol. (1998) [Pubmed]
  26. Increased acid exposure in patients with gastroesophageal reflux disease influences cyclooxygenase-2 gene expression in the squamous epithelium of the lower esophagus. Hamoui, N., Peters, J.H., Schneider, S., Uchida, K., Yang, D., Vallböhmer, D., Valboehmer, D., Hagen, J.A., DeMeester, S.R., DeMeester, T.R., Danenberg, K., Danenberg, P. Archives of surgery (Chicago, Ill. : 1960) (2004) [Pubmed]
  27. Aberrant expression of CDX2 in Barrett's epithelium and inflammatory esophageal mucosa. Eda, A., Osawa, H., Satoh, K., Yanaka, I., Kihira, K., Ishino, Y., Mutoh, H., Sugano, K. J. Gastroenterol. (2003) [Pubmed]
  28. Loss of function of Trp53, but not Apc, leads to the development of esophageal adenocarcinoma in mice with jejunoesophageal reflux. Fein, M., Peters, J.H., Baril, N., McGarvey, M., Chandrasoma, P., Shibata, D., Laird, P.W., Skinner, K.A. J. Surg. Res. (1999) [Pubmed]
  29. Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism. Mishra, A., Rothenberg, M.E. Gastroenterology (2003) [Pubmed]
  30. Biphasic effect of prostaglandin E2 in a rat model of esophagitis mediated by EP1 receptors: relation to pepsin secretion. Yamato, M., Nagahama, K., Kotani, T., Kato, S., Takeuchi, K. Digestion (2005) [Pubmed]
  31. Randomized, double-blind, placebo-controlled crossover trial of cimetidine and pirenzepine in nonulcer dyspepsia. Talley, N.J., McNeil, D., Hayden, A., Piper, D.W. Gastroenterology (1986) [Pubmed]
  32. Double-blind controlled trial of bethanechol and antacid versus placebo and antacid in the treatment of erosive esophagitis. Saco, L.S., Orlando, R.C., Levinson, S.L., Bozymski, E.M., Jones, J.D., Frakes, J.T. Gastroenterology (1982) [Pubmed]
  33. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter Study. Sontag, S.J., Hirschowitz, B.I., Holt, S., Robinson, M.G., Behar, J., Berenson, M.M., McCullough, A., Ippoliti, A.F., Richter, J.E., Ahtaridis, G. Gastroenterology (1992) [Pubmed]
  34. Nissen fundoplication for reflux esophagitis. Long-term clinical and endoscopic results in 109 of 127 consecutive patients. Luostarinen, M. Ann. Surg. (1993) [Pubmed]
  35. Healing of erosive esophagitis with sucralfate and cimetidine: influence of pretreatment lower esophageal sphincter pressure and serum pepsinogen I levels. Ros, E., Toledo-Pimentel, V., Bordas, J.M., Grande, L., Lacima, G., Segu, L. Am. J. Med. (1991) [Pubmed]
WikiGenes - Universities